These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Li C; Guo Y; Xie W; Li X; Janokovic J; Le W Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141 [TBL] [Abstract][Full Text] [Related]
4. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424 [TBL] [Abstract][Full Text] [Related]
5. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype. Merlo S; Canonico PL; Sortino MA Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591 [TBL] [Abstract][Full Text] [Related]
6. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. Chernoloz O; El Mansari M; Blier P J Psychiatry Neurosci; 2012 Feb; 37(2):113-21. PubMed ID: 22023785 [TBL] [Abstract][Full Text] [Related]
7. Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease. Kubota H; Zhou X; Zhang X; Watanabe H; Nagai T Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201535 [TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effect of pramipexole in an inflammatory model of depression. Lieberknecht V; Cunha MP; Junqueira SC; Coelho ID; de Souza LF; Dos Santos AR; Rodrigues AL; Dutra RC; Dafre AL Behav Brain Res; 2017 Mar; 320():365-373. PubMed ID: 27825895 [TBL] [Abstract][Full Text] [Related]
10. Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption. Souza PS; Gonçalves ED; Pedroso GS; Farias HR; Junqueira SC; Marcon R; Tuon T; Cola M; Silveira PCL; Santos AR; Calixto JB; Souza CT; de Pinho RA; Dutra RC Mol Neurobiol; 2017 Aug; 54(6):4723-4737. PubMed ID: 27447807 [TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Du F; Li R; Huang Y; Li X; Le W Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585 [TBL] [Abstract][Full Text] [Related]
12. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. Ling ZD; Robie HC; Tong CW; Carvey PM J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005 [TBL] [Abstract][Full Text] [Related]
13. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor. Junqueira SC; Dos Santos Coelho I; Lieberknecht V; Cunha MP; Calixto JB; Rodrigues ALS; Santos ARS; Dutra RC Mol Neurobiol; 2017 Jul; 54(5):3271-3285. PubMed ID: 27130268 [TBL] [Abstract][Full Text] [Related]
14. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804 [TBL] [Abstract][Full Text] [Related]
15. The adverse effects of pramipexole on probability discounting are not reversed by acute D Orrù M; Strathman HJ; Floris G; Scheggi S; Levant B; Bortolato M Eur Neuropsychopharmacol; 2020 Mar; 32():104-119. PubMed ID: 31983530 [TBL] [Abstract][Full Text] [Related]
16. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789 [TBL] [Abstract][Full Text] [Related]
17. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses. Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996 [TBL] [Abstract][Full Text] [Related]
18. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Breuer ME; Groenink L; Oosting RS; Buerger E; Korte M; Ferger B; Olivier B Eur J Pharmacol; 2009 Aug; 616(1-3):134-40. PubMed ID: 19549514 [TBL] [Abstract][Full Text] [Related]
19. Three paradoxes related to the mode of action of pramipexole: The path from D2/D3 dopamine receptor stimulation to modification of dopamine-modulated functions. Szabadi E J Psychopharmacol; 2024 Jul; 38(7):581-596. PubMed ID: 39041250 [TBL] [Abstract][Full Text] [Related]
20. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Siuciak JA; Fujiwara RA Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]